Novel therapeutics in rare genetic obesities: A narrative review
- PMID: 37037398
- DOI: 10.1016/j.phrs.2023.106763
Novel therapeutics in rare genetic obesities: A narrative review
Abstract
The better understanding of the molecular causes of rare genetic obesities and its associated phenotype involving the hypothalamus allows today to consider innovative therapeutics focused on hunger control. Several new pharmacological molecules benefit patients with monogenic or syndromic obesity. They are likely to be among the treatment options for these patients in the coming years, helping clinicians and patients prevent rapid weight progression and eventually limit bariatric surgery procedures, which is less effective in these patients. Their positioning in the management of such patients will be needed to be well defined to develop precision medicine in genetic forms of obesity.
Keywords: Childhood obesity; Genetics; Hypothalamus; Melanocortins; Monogenic obesity.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dubern reports a relationship with rhythm Pharmaceuticals, Novo Nordisks that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical